1150 GMT - Merck KGaA anticipates its research and development costs will normalize to industry-peer levels as its pipeline advances and recent deals mature, Chief Executive Officer Belen Garijo says in a media call. The life-sciences and electronics company's R&D spending was 2.3 billion euros in 2024, and it expects it to gradually increase in 2025. Garijo reaffirms Merck's strategy to bolster in-licensing--agreements to use another company's products--and consider smaller mergers and acquisitions to strengthen its pipeline. Merck is looking for new assets as one of its key growth drivers, multiple sclerosis drug Mavenclad, will face patent expiry in 2026. The German company's goal is to achieve a 50-50 split between internal and external innovation for future product launches, Garijo adds. Shares are up 1.6% at 139.30 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 06, 2025 06:50 ET (11:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。